- Home
- IPDN vs BCAB Comparison
IPDN vs BCAB Comparison
Compare IPDN & BCAB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | IPDN | BCAB |
|---|---|---|
| Founded | 2003 | 2007 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | EDP Services | Medicinal Chemicals and Botanical Products |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 6.6M | 5.9M |
| IPO Year | 2012 | 2020 |
Fundamental Metrics
Financial Performance| Metric | IPDN | BCAB |
|---|---|---|
| Price | $0.22 | $3.04 |
| Analyst Decision | | Hold |
| Analyst Count | 0 | 1 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 581.5K | 47.9K |
| Earning Date | 05-15-2026 | 05-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 29.86 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $22,054,219.00 | $300,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.20 | $0.12 |
| 52 Week High | $12.39 | $6.52 |
Technical Indicators
Market Signals| Indicator | IPDN | BCAB |
|---|---|---|
| Relative Strength Index (RSI) | 29.37 | 36.30 |
| Support Level | N/A | $0.17 |
| Resistance Level | $0.46 | $4.24 |
| Average True Range (ATR) | 0.06 | 0.28 |
| MACD | -0.01 | -0.03 |
| Stochastic Oscillator | 11.06 | 22.26 |
Price Performance
Historical ComparisonAbout IPDN Professional Diversity Network Inc.
Professional Diversity Network Inc provides access to networking, training, educational, and employment services to its registered users. It has three operating segments: the TalentAlly Network segment, which maintains and operates job board software and hosts career fairs; the National Association of Professional Women (NAPW) segment, which is a women-only professional networking organization; the RemoteMore segment; and Corporate Overhead. The company generates the majority of its revenue from the TalentAlly Network Segment.
About BCAB BioAtla Inc.
BioAtla Inc is a clinical-stage biopharmaceutical company. The company is engaged in the development of a novel class of specific and selective antibody-based therapeutics for the treatment of solid tumor cancer. Its pipeline products comprise mecbotamab vedotin (BA3011), ozuriftamab vedotin (BA3021), and evalstotug (BA3071), and its Phase 1 clinical trial of BA3182 (CAB-EpCAM x CAB-CD3) and Bispecific antibody programs. The company's operations are organized on a single reportable segment, which includes all activities related to the discovery, development, and commercialization of its CAB products.